Noah Goodman
About Noah Goodman
Noah Goodman is Chief Business Officer at Kymera Therapeutics, appointed in April 2025; he is 38 years old with a B.S. in Neuroscience (University of Michigan) and an MBA in Health Care Management (Wharton) . He brings 15+ years in life sciences business development, including President & Chief Business Officer roles at nChroma Bio/Chroma Medicine, and prior BD leadership at Cadent Therapeutics, Seres Therapeutics, and Spark Therapeutics . Context on company performance since his appointment: Kymera reported Q1 2025 collaboration revenue of $22.1M (up from $10.3M in Q1 2024), recorded a $20M Sanofi milestone, net loss of $65.6M, and cash/ investments of $775M with runway into H1 2028 . The 2025 proxy outlines an executive pay philosophy emphasizing at-risk pay, anti-hedging/pledging, clawbacks, and double-trigger change-in-control protections .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| nChroma Bio / Chroma Medicine | President & Chief Business Officer | May 2021 – Apr 2025 | Led BD strategy through merger with Nvelop Therapeutics; senior leadership in gene editing platform company |
| Cadent Therapeutics (acquired by Novartis) | Executive Director & Head of Business Development | Aug 2019 – Mar 2021 | Drove BD leading to eventual acquisition by Novartis; CNS therapeutics focus |
| Seres Therapeutics | Business Development roles | Earlier career (dates not specified) | Led collaborations/licensing across therapeutic areas in microbiome therapeutics |
| Spark Therapeutics | Business Development roles | Earlier career (dates not specified) | BD contributions at gene therapy leader; transaction experience |
| Easton Associates | Senior Consultant | Earlier career (dates not specified) | Life sciences consultancy; strategic advisory foundation |
External Roles
- No current public company directorships or committee roles disclosed for Noah Goodman in company filings .
Fixed Compensation
- Not disclosed for Noah Goodman as of the latest DEF 14A (2025 proxy covers FY2024 NEOs; Goodman joined April 2025 and is not included) .
- Company program targets base salary around the 50th percentile of peer group; annual reviews and market benchmarking are used (policy-level guidance) .
Performance Compensation
| Component | Metric | Weighting | Target | Actual | Payout | Vesting |
|---|---|---|---|---|---|---|
| Annual Cash Incentive Plan | Corporate and individual goals (financial/operational) | Not specified per individual | Target % set annually; for NEOs historically 40%–60% of salary | Not disclosed for Goodman | Not disclosed for Goodman | Annual cash bonus; must be employed on payment date |
| Performance Stock Units (PSUs) | Clinical milestones (3 total) | 40% (Milestone 1) | Target Amount (company-set) | Not yet disclosed | 0–100% of Target Amount | No vesting before first anniversary; vests 40%/40%/20% upon achieving three milestones |
| Long-term Equity (Options/RSUs) | Time-based vesting | N/A | N/A | N/A | N/A | Company policy includes options and RSUs with multi-year vesting; executives’ LTI to include performance-based equity beginning 2025 |
Notes
- In January 2025, the Compensation & Talent Committee introduced PSUs for key employees including the management team; vesting tied to clinical milestones with a 1-year vesting gate .
- The annual bonus framework exists, but Goodman-specific targets or payouts have not been disclosed in filings to date .
Equity Ownership & Alignment
- Beneficial ownership: Goodman is not listed among executive officers/directors in the March 31, 2025 beneficial ownership table (which includes CEO, CFO, CMO, CLO, COO, and directors), implying no disclosed beneficial holdings or holdings below disclosure thresholds as of that date .
- Anti-hedging/pledging: Company prohibits hedging, margin, short sales, derivatives, and generally prohibits pledging; no waivers requested or approved to date .
- Clawback: Nasdaq-compliant compensation recovery policy adopted (Nov 1, 2023); applies to incentive-based comp tied to financial reporting measures for the prior three fiscal years if restatement occurs; filed as Exhibit 97 to FY2024 Form 10-K .
Employment Terms
- Appointment: Goodman joined Kymera as Chief Business Officer in April 2025 .
- Change-in-control: Company indicates use of double-trigger change-in-control protection for executive officers (limited exceptions), consistent with governance best practices .
- Covenants: Company historically requires executives to enter standard confidential information, invention assignment, nonsolicitation, and noncompetition agreements (precedent for NEOs; Goodman’s specific agreement not disclosed) .
- Severance specifics: Not disclosed for Goodman; company’s severance/change-in-control philosophy aims to provide cash continuity, COBRA benefits continuity, and equity acceleration in certain circumstances for NEOs per precedent agreements (example terms disclosed for CEO) .
Investment Implications
- Alignment: Introduction of PSUs with milestone-based vesting and a one-year vesting gate indicates pay-for-performance alignment and reduces near-term insider selling pressure until vesting eligibility begins .
- Governance quality: Anti-hedging/pledging, clawback policy, and double-trigger CIC protections support shareholder-friendly practices and reduce misalignment risks .
- Retention: Multi-year equity vesting and milestone-tied PSUs enhance retention incentives for a newly appointed CBO leading BD during pipeline expansion and collaborations; Q1 2025 Sanofi milestone and elevated collaboration revenue provide operating momentum to monetize BD strategy .
- Data gaps: Compensation specifics (base, bonus targets, equity grant sizes) and beneficial ownership for Goodman are not yet disclosed; monitor upcoming 8-Ks and the 2026 proxy for offer letter terms, PSU grant amounts, and ownership updates to refine pay-for-performance and trading signal analyses .